Publications
-
Stage I testicular seminoma: a SEER analysis of contemporary adjuvant radiotherapy trends.
Thong AE,
Lichtensztajn DY, Almario L, Ingels A, Gomez SL, Gonzalgo ML.
J Urol.
2013
-
Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
Wang H,
Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML.
Urol Oncol.
2012 Jul-Aug;
30
(4):
428-33
-
Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center.
Albadine R,
Hyndman ME, Chaux A, Jeong JY, Saab S, Tavora F, Epstein JI, Gonzalgo ML, Pavlovich CP, Netto GJ.
Hum Pathol.
2012;
43
(2):
254-60
-
Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes.
Willis DL,
Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM.
BJU Int.
2012;
109
(6):
898-905
-
Learning from our patients: complications and the future of radical cystectomy for bladder cancer.
Thong AE,
Gonzalgo ML.
J Urol.
2012;
187
(6):
2018
-
Editorial comment.
Liu JJ,
Gonzalgo ML.
J Urol.
2011;
185
(1):
35-6
-
Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching.
Magheli A,
Gonzalgo ML, Su LM, Guzzo TJ, Netto G, Humphreys EB, Han M, Partin AW, Pavlovich CP.
BJU Int.
2011;
107
(12):
1956-62
-
Minimally invasive training in urologic oncology.
Liu JJ,
Gonzalgo ML.
Arch Esp Urol.
2011;
64
(9):
865-8
-
Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.
Makarov DV,
Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, Han M.
World J Urol.
2011;
29
(1):
11-4
-
Use of magnetic resonance imaging to accurately detect and stage prostate cancer: the hype and the hope.
Wu J,
Gonzalgo ML.
J Urol.
2011;
186
(5):
1756-7
-
Prognostic features and markers for testicular cancer management.
Leman ES,
Gonzalgo ML.
Indian J Urol.
2010 Jan-Mar;
26
(1):
76-81
-
Editorial comment.
Ngo TC,
Gonzalgo ML.
J Urol.
2010;
183
(5):
1750
-
Editorial comment.
Chang SL,
Gonzalgo ML.
J Urol.
2010;
183
(2):
459; discussion 459
-
Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.
Schultz L,
Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Nielsen ME, Neilsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ.
Cancer.
2010;
116
(23):
5517-26
-
Laparoscopic retroperitoneal lymph node dissection with therapeutic intent in men with clinical stage I nonseminomatous germ cell tumors.
Guzzo TJ,
Gonzalgo ML, Allaf ME.
J Endourol.
2010;
24
(11):
1759-63
-
Renal pseudoaneurysm: an overview.
Ngo TC,
Lee JJ, Gonzalgo ML.
Nat Rev Urol.
2010;
7
(11):
619-25
-
Robotic surgical training of the urologic oncologist.
Guzzo TJ,
Gonzalgo ML.
Urol Oncol.
2009 Mar-Apr;
27
(2):
214-7
-
Training the urologic oncologist of the future: where are the challenges?
Gonzalgo ML,
Urol Oncol.
2009 Mar-Apr;
27
(2):
192
-
Editorial comment.
Gonzalgo ML,
J Urol.
2009;
182
(4):
1311-2
-
Editorial comment.
Gonzalgo ML,
J Urol.
2009;
182
(3):
913
-
Editorial comment.
Gonzalgo ML,
J Urol.
2009;
182
(5):
2380-1
-
Editorial comment.
Magheli A,
Gonzalgo ML.
J Urol.
2009;
182
(5):
2248; discussion 2248-9
-
Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer.
Guzzo TJ,
Magheli A, Bivalacqua TJ, Nielsen ME, Attenello FJ, Schoenberg MP, Gonzalgo ML.
Urology.
2009;
74
(6):
1276-80
-
Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'.
Eggener S,
Gonzalgo M, Yossepowitch O.
Br J Cancer.
2009;
101
(12):
2057-8; author reply 2059
-
Reply.
Guzzo TJ,
Gonzalgo ML.
Urology.
2009;
74
(6):
1281
-
Surgery: laparoscopic prostatectomy: learning curve and cancer control.
Chang SL,
Gonzalgo ML.
Nat Rev Urol.
2009;
6
(7):
361-2
-
Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system.
Trock BJ,
Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI.
J Urol.
2009;
182
(4):
1364-70
-
Urethral carcinosarcoma from bladder carcinosarcomatous lesions: analysis of clinicopathological features.
Bivalacqua TJ,
Bagga HS, Patil K, Magheli A, Taube JM, Guzzo TJ, Gonzalgo ML.
Can J Urol.
2009;
16
(1):
4512-5
-
Words of wisdom. Re: Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. Hellenthal NJ, Ramirez ML, Evans CP, deVere White RW, Koppie TM.
Gonzalgo ML,
Parekh DJ.
Eur Urol.
2009;
56
(3):
571-2
-
Application of Evicel to cavernous nerves of the rat does not influence erectile function in vivo.
Bivalacqua TJ,
Guzzo TJ, Schaeffer EM, Gebska MA, Champion HC, Burnett AL, Gonzalgo ML.
Urology.
2008;
72
(5):
1169-73
-
Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.
Magheli A,
Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.
Urology.
2008;
72
(6):
1246-51
-
Minimally invasive surgical approaches and management of prostate cancer.
Gonzalgo ML,
Patil N, Su LM, Patel VR.
Urol Clin North Am.
2008;
35
(3):
489-504, ix
-
Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
Guzzo TJ,
Rogers CG, Deng CY, Bivalacqua TJ, Palapattu GS, Bastian PJ, Eisenberger MA, Schoenberg MP, Gonzalgo ML.
BJU Int.
2008;
102
(11):
1539-43
-
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
Müntener M,
Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh PC, Partin AW, Nielsen ME.
Eur Urol.
2008;
53
(4):
767-75; discussion 775-6
-
Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
Magheli A,
Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.
J Urol.
2008;
179
(5):
1780-4; discussion 1784
-
The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer.
Gonzalgo ML,
Datar RH, Schoenberg MP, Cote RJ.
Urol Oncol.
2007 May-Jun;
25
(3):
228-35
-
Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A,
Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.
J Urol.
2007;
178
(5):
1933-7; discussion 1937-8
-
Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A,
Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Gonzalgo ML.
J Urol.
2007;
178
(4 Pt 1):
1311-5
-
Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation.
Gonzalgo ML,
Liang G.
Nat Protoc.
2007;
2
(8):
1931-6
-
Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A,
Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML.
J Urol.
2007;
178
(4 Pt 1):
1277-80; discussion 1280-1
-
Update on PSA testing.
Gonzalgo ML,
Carter HB.
J Natl Compr Canc Netw.
2007;
5
(7):
737-42
-
Visual vignette. Adrenal myelolipoma.
Gonzalgo ML,
Su LM, Basaria S.
Endocr Pract.
2006 Jan-Feb;
12
(1):
109
-
Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ,
Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ.
Cancer.
2006;
107
(6):
1265-72
-
Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging.
Krishnan M,
Park JM, Cao F, Wang D, Paulmurugan R, Tseng JR, Gonzalgo ML, Gambhir SS, Wu JC.
FASEB J.
2006;
20
(1):
106-8
-
Genitourinary myiasis (maggot infestation).
Makarov DV,
Bagga H, Gonzalgo ML.
Urology.
2006;
68
(4):
889
-
High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
Rogers CG,
Gonzalgo ML, Yan G, Bastian PJ, Chan DY, Nelson WG, Pavlovich CP.
J Urol.
2006;
176
(5):
2280-4
-
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Gonzalgo ML,
Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin AW.
Urology.
2006;
67
(1):
115-9
-
Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer.
Nielsen ME,
Gonzalgo ML, Schoenberg MP, Getzenberg RH.
World J Urol.
2006;
24
(5):
499-508
-
Classification and trends of perioperative morbidities following laparoscopic radical prostatectomy.
Gonzalgo ML,
Pavlovich CP, Trock BJ, Link RE, Sullivan W, Su LM.
J Urol.
2005;
174
(1):
135-9; discussion 139
-
Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis.
Gonzalgo ML,
Nakayama M, Lee SM, De Marzo AM, Nelson WG.
Urology.
2004;
63
(2):
414-8
-
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG,
Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI, Huland H, Yoo C, Tsai YC, Nichols PW, Bochner BH, Jones PA, Liang G.
Clin Cancer Res.
2004;
10
(22):
7457-65
-
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M,
Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG.
J Cell Biochem.
2004;
91
(3):
540-52
-
Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S,
Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG.
Cancer Res.
2004;
64
(6):
1975-86
-
Laparoscopic-assisted nephrectomy with inferior vena cava tumor thrombectomy: preliminary results.
Varkarakis IM,
Bhayani SB, Allaf ME, Inagaki T, Gonzalgo ML, Jarrett TW.
Urology.
2004;
64
(5):
925-9
-
Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis.
Gonzalgo ML,
Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, Pavlovich CP.
Clin Cancer Res.
2004;
10
(21):
7276-83
-
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Rogers CG,
Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP.
J Urol.
2004;
172
(4 Pt 1):
1501-3
-
Balloon cuffing and management of the entrapped Foley catheter.
Gonzalgo ML,
Walsh PC.
Urology.
2003;
61
(4):
825-7
-
Clinical efficacy of sildenafil citrate and predictors of long-term response.
Gonzalgo ML,
Brotzman M, Trock BJ, Geringer AM, Burnett AL, Jarow JP.
J Urol.
2003;
170
(2 Pt 1):
503-6
-
Endoscopic basket extraction of a urethral foreign body.
Gonzalgo ML,
Chan DY.
Urology.
2003;
62
(2):
352
-
Molecular pathways to prostate cancer.
Gonzalgo ML,
Isaacs WB.
J Urol.
2003;
170
(6 Pt 1):
2444-52
-
Persistent purulent drainage from the glans penis: atypical presentation of pyoderma gangrenosum.
Gonzalgo ML,
de Lacerda DA, De Marzo AM, Chan DY.
J Urol.
2003;
169
(5):
1793-4
-
Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
Gonzalgo ML,
Pavlovich CP, Lee SM, Nelson WG.
Clin Cancer Res.
2003;
9
(7):
2673-7
-
Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction.
Liang G,
Gonzalgo ML, Salem C, Jones PA.
Methods.
2002;
27
(2):
150-5
-
Prognostic significance of preoperative molecular serum analysis in renal cancer.
Gonzalgo ML,
Eisenberger CF, Lee SM, Trock BJ, Marshall FF, Hortopan S, Sidransky D, Schoenberg MP.
Clin Cancer Res.
2002;
8
(6):
1878-81
-
Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE).
Gonzalgo ML,
Jones PA.
Methods.
2002;
27
(2):
128-33
-
Biological pathways to bladder carcinogenesis.
Gonzalgo ML,
Schoenberg MP, Rodriguez R.
Semin Urol Oncol.
2000;
18
(4):
256-63
-
Roles of cell division and gene transcription in the methylation of CpG islands.
Bender CM,
Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones PA.
Mol Cell Biol.
1999;
19
(10):
6690-8
-
DNA methylation in bladder cancer.
Jones PA,
Gonzalgo ML, Tsutsumi M, Bender CM.
Eur Urol.
1998:
33 Suppl 4
7-8
-
Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
Tsutsumi M,
Tsai YC, Gonzalgo ML, Nichols PW, Jones PA.
Oncogene.
1998;
17
(23):
3021-7
-
The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
Gonzalgo ML,
Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA.
Cancer Res.
1998;
58
(6):
1245-52
-
Altered DNA methylation and genome instability: a new pathway to cancer?
Jones PA,
Gonzalgo ML.
Proc Natl Acad Sci U S A.
1997;
94
(6):
2103-5
-
Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR.
Gonzalgo ML,
Liang G, Spruck CH, Zingg JM, Rideout WM, Jones PA.
Cancer Res.
1997;
57
(4):
594-9
-
Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
Gonzalgo ML,
Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW.
Cancer Res.
1997;
57
(23):
5336-47
-
Mutagenic and epigenetic effects of DNA methylation.
Gonzalgo ML,
Jones PA.
Mutat Res.
1997;
386
(2):
107-18
-
Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE).
Gonzalgo ML,
Jones PA.
Nucleic Acids Res.
1997;
25
(12):
2529-31
-
Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR,
Spruck CH, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA.
Cancer Res.
1996;
56
(21):
5039-43
-
The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline.
Yang AS,
Gonzalgo ML, Zingg JM, Millar RP, Buckley JD, Jones PA.
J Mol Biol.
1996;
258
(2):
240-50
-
High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M,
Shibata A, Ohneseit PF, Spruck CH, Busch C, Shamaa M, El-Baz M, Nichols PW, Gonzalgo ML, Elbaz M [corrected to El-Baz M].
J Natl Cancer Inst.
1995;
87
(18):
1383-93
-
Comparison of strategies to detect and quantitate uniquely marked cells in intra- and inter-species hemopoietic chimeras.
Pallavicini MG,
Langlois RG, Reitsma M, Gonzalgo M, Sudar D, Montoya T, Weier HU, Haendel S.
Cytometry.
1992;
13
(4):
356-67
-
Hemopoietic chimerism in rodents transplanted in utero with fetal human hemopoietic cells.
Pallavicini MG,
Flake AW, Madden D, Bethel C, Duncan B, Gonzalgo ML, Haendel S, Montoya T, Roberts L.
Transplant Proc.
1992;
24
(2):
542-3
Navigation for This Section: Stanford Hospital & Clinics
Additional Links: Hospital Services
FIND A PHYSICIAN
Help